These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32064510)

  • 1. Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic Review and Meta-analysis.
    Shah R; Hoffman GR; El-Dallal M; Goldowsky AM; Chen Y; Feuerstein JD
    J Crohns Colitis; 2020 Sep; 14(8):1057-1065. PubMed ID: 32064510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
    Sethi S; Dias S; Kumar A; Blackwell J; Brookes MJ; Segal JP
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1362-1374. PubMed ID: 36495020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
    Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
    Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
    Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis.
    Zheng FY; Yang KS; Min WC; Li XZ; Xing Y; Wang S; Zhang YS; Zhao QC
    World J Gastrointest Surg; 2024 Feb; 16(2):571-584. PubMed ID: 38463352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
    Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
    J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
    Yao J; Jiang X; You JHS
    Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out.
    Agrawal M; Dubinsky MC; Colombel JF
    J Crohns Colitis; 2020 Sep; 14(8):1035-1036. PubMed ID: 32894298
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
    Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis.
    Dong W; Hu X; Wu C; Wang G; Fang Y; Shi L; Nie X
    Semin Arthritis Rheum; 2023 Dec; 63():152302. PubMed ID: 37951128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Battat R; Long MD
    Am J Gastroenterol; 2021 Oct; 116(10):2029-2031. PubMed ID: 34515666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
    Porth R; Deyhim T; Zullow S; Rabinowitz LG; Grossberg LB; Roblin X; Paul S; Cheifetz AS; Papamichael K
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.